SCHEMBL1491102

SCHEMBL1491102

Nc1ccnn1Cc1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 1.00
PKM P14618 1/20 1.00
KDM4E B2RXH2 1/20 0.64
CHRNB2 P17787 1/20 0.49
CHRNA4 P43681 1/20 0.49
CYP11B1 P15538 1/20 0.47
ADORA2A P29274 2/20 0.47
ADORA1 P30542 2/20 0.47
P2RX7 Q99572 5/20 0.47
CHRNA7 P36544 1/20 0.46
TRPA1 O75762 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
ADORA2B P29275 1/20 0.43
CYP2A6 P11509 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL568868 0.82 KDM4E (0.72) ALDH1A1PKMKDM4EP2RX7
SCHEMBL22516943 0.79 ALDH1A1 (0.66) ALDH1A1PKMCHRNB2CHRNA4CYP11B1
SCHEMBL6760429 0.79 KDM4E (0.81) ALDH1A1PKMKDM4ECYP11B1P2RX7
SCHEMBL1491110 0.78 KDM4E (1.00) ALDH1A1PKMKDM4ECYP11B1P2RX7
SCHEMBL13989341 0.78 ALDH1A1 (0.64) ALDH1A1PKMCHRNB2CHRNA4CYP11B1
SCHEMBL14480143 0.76 ALDH1A1 (0.61) ALDH1A1PKMCHRNB2CHRNA4CYP11B1
SCHEMBL27514958 0.76 ALDH1A1 (0.61) ALDH1A1PKMKDM4ECHRNB2CHRNA4
SCHEMBL17076874 0.76 ALDH1A1 (0.60) ALDH1A1PKMCHRNB2CHRNA4CYP11B1
SCHEMBL14221993 0.74 ALDH1A1 (0.59) ALDH1A1PKMCHRNB2CHRNA4P2RX7
SCHEMBL16832377 0.74 KDM4E (0.69) ALDH1A1PKMKDM4ECHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312722-B2 Hsp90 inhibitors and uses thereof TRUSTEES OF BOSTON UNIVERSITY (US) 2022-04-26 US disclosed
US-20200354373-A1 HSP90 INHIBITORS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2020-11-12 US disclosed
WO-2020227368-A1 HSP90 INHIBITORS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2020-11-12 WO disclosed
WO-2014202152-A1 NEW COSMETIC COMPOSITIONS COMPRISING CATIONIC DYES AND PROCESS FOR DIRECT DYEING OF KERATIN FIBERS ALFA PARF GROUP S.P.A. (IT) 2014-12-24 WO disclosed
WO-2014202150-A1 NEW CATIONIC DYES, KITS AND COMPOSITIONS THEREOF, AND PROCESS FOR DYEING KERATIN FIBERS ALFA PARF GROUP S.P.A. (IT) 2014-12-24 WO disclosed
WO-2014202150-A1 NEW CATIONIC DYES, KITS AND COMPOSITIONS THEREOF, AND PROCESS FOR DYEING KERATIN FIBERS ALFA PARF GROUP S.P.A. (IT) 2014-12-24 WO disclosed
WO-2014202152-A1 NEW COSMETIC COMPOSITIONS COMPRISING CATIONIC DYES AND PROCESS FOR DIRECT DYEING OF KERATIN FIBERS ALFA PARF GROUP S.P.A. (IT) 2014-12-24 WO disclosed
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-04-14 US disclosed
EP-2288603-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2011-03-02 EP disclosed
WO-2009150614-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-12-17 WO disclosed
US-7462204-B2 Cationic diaminopyrazoles, a process for producing them and colorants containing these compounds WELLA AG (DE) 2008-12-09 US disclosed
US-20070056120-A1 Cationic diaminopyrazoles, a process for producing them and colorants containing these compounds HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) 2007-03-15 US disclosed
EP-1687280-A1 CATIONIC DIAMINOPYRAZOLES, A METHOD FOR THE PRODUCTION THEREOF AND DYES CONTAINING THESE COMPOUNDS Wella Aktiengesellschaft (DE) 2006-08-09 EP disclosed
WO-2005051918-A1 CATIONIC DIAMINOPYRAZOLES, A METHOD FOR THE PRODUCTION THEREOF AND DYES CONTAINING THESE COMPOUNDS WELLA AKTIENGESELLSCHAFT (DE) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354373-A1 HSP90 INHIBITORS AND USES THEREOF HSP90AB1, HSP90B1, HSP90AA1 ALDH1A1 2482/4885PKM 3236/4885KDM4E 1421/4885
US-20110086889-A1 TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R ALDH1A1 3233/4885PKM 2177/4885KDM4E 2955/4885
US-20070056120-A1 Cationic diaminopyrazoles, a process for producing them and colorants containing these compounds KRT18, DSP, TUBA4A ALDH1A1 978/4885PKM 463/4885KDM4E 534/4885
US-11312722-B2 Hsp90 inhibitors and uses thereof HSP90AB1, HSP90B1, HSP90AA1 ALDH1A1 2482/4885PKM 3236/4885KDM4E 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.